Drug Profile
Research programme: recombinant human lysosomal proteinases - Halozyme Therapeutics
Alternative Names: Metalloproteinase temperature selective recombinant enzyme - Halozyme Therapeutics; MMP1ts; Recombinant enzymes for dermatology - Halozyme TherapeuticsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Halozyme Therapeutics
- Class Peptide hydrolases
- Mechanism of Action Protease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dupuytren's contracture; Peyronie's disease; Scars
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Scars in USA (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for research development in Dupuytren's-contracture in USA
- 04 Nov 2017 No recent reports of development identified for research development in Peyronie's-disease in USA